Worldwide Long-Acting Injectable Antipsychotics Market Insights: Industry Size, Growth Analysis and Forecast
Report ID : 1335949 | Published : May 2025 | Study Period : 2023-2033 | Format : PDF + Excel
The market size of the Long-Acting Injectable Antipsychotics Market is categorized based on Drug Type (Risperidone, Paliperidone, Aripiprazole, Olanzapine, Fluphenazine) and Indication (Schizophrenia, Bipolar Disorder, Depression, Other Psychiatric Disorders) and Administration Route (Intramuscular, Subcutaneous) and Formulation (Solution, Suspension) and geographical regions (North America, Europe, Asia-Pacific, South America, and Middle-East and Africa).
In 2023, the Long-Acting Injectable Antipsychotics Market size was USD 3.5 billion and is projected to grow to USD 7.1 billion by 2033, registering a CAGR of 7.4% from 2024 to 2033. This report includes multiple segments and provides an analysis of key trends and factors playing a substantial role in the market.
The market for Long Acting Injectable Antipsychotics (LAIAs) has been changing rapidly, due to the increase in people with mental disorders and the focus on how these issues are treated. LAIAs have been integrated into healthcare systems across the globe as a key tool in improving adherence and decreasing relapse rates among patients with chronic psychiatric disorders. This modern branch tackles treatment adherence challenges and demonstrates the improving appreciation of mental health in general.
The describe the rapid growth of LAIA market, stakeholders from all classes, including pharmaceutical companies, healthcare practitioners, and patients themselves are beginning to see the benefits of long-lasting therapy. This innovation is expected to help with consistent medication reminders and lower the routine administration of pills. With mental health emerging as the focus of many health debates, there is a projected increase in the market for effective antipsychotic medication which further confirms the acceptance of LAIs in modern day healthcare.
| ATTRIBUTES | DETAILS |
| STUDY PERIOD | 2023-2033 |
| BASE YEAR | 2023 |
| FORECAST PERIOD | 2024-2033 |
| HISTORICAL PERIOD | 2023-2024 |
| UNIT | VALUE (USD BILLION) |
| KEY COMPANIES PROFILED | Johnson & Johnson, Roche, Otsuka Pharmaceutical, Lundbeck, Teva Pharmaceutical Industries, Mylan N.V., Eisai Co. Ltd., Hikma Pharmaceuticals, Akorn Inc., Sumitomo Dainippon Pharma, AstraZeneca |
| SEGMENTS COVERED |
By Drug Type - Risperidone, Paliperidone, Aripiprazole, Olanzapine, Fluphenazine
By Indication - Schizophrenia, Bipolar Disorder, Depression, Other Psychiatric Disorders
By Administration Route - Intramuscular, Subcutaneous
By Formulation - Solution, Suspension
By Geography - North America, Europe, APAC, Middle East Asia & Rest of World. |
Long-Acting Injectable Antipsychotics Market Dynamics
The Long-Acting Injectable Antipsychotics Market is undergoing significant changes due to various dynamic factors. This section delves into the key drivers, restraints, opportunities, and challenges that are shaping the market landscape.
Market Drivers
- Technological Advancements
- Increasing Consumer Demand
- Regulatory Support
- Globalization
Market Restraints
- High Operational Costs
- Regulatory Challenges
- Market Saturation
Market Opportunities
- Emerging Markets
- Product Innovation
- Strategic Partnerships
Market Challenges
- Technological Disruptions
- Supply Chain Issues
- Changing Consumer Preferences
Long-Acting Injectable Antipsychotics Market Segmentations
Market Breakup by Drug Type
- Overview
- Risperidone
- Paliperidone
- Aripiprazole
- Olanzapine
- Fluphenazine
Market Breakup by Indication
- Overview
- Schizophrenia
- Bipolar Disorder
- Depression
- Other Psychiatric Disorders
Market Breakup by Administration Route
- Overview
- Intramuscular
- Subcutaneous
Market Breakup by Formulation
- Overview
- Solution
- Suspension
Market Breakup by Region
North America
- United States of America
- Canada
- Mexico
Europe
- United Kingdom
- Germany
- France
- Italy
- Spain
- Others
Asia Pacific
- China
- Japan
- India
- ASEAN
- Australia
- Others
Latin America
- Brazil
- Argentina
- Mexico
- Others
Middle East and Africa
- Saudi Arabia
- United Arab Emirates
- Nigeria
- South Africa
- Others
Key Players in the Long-Acting Injectable Antipsychotics Market
This report provides an in-depth analysis of both established and rising industry participants. It provides broad lists of important companies organized by the types of products they offer and other market-related factors. In addition to characterizing these companies, the report contains the year each player entered the market, which is useful for research analysis by the study's analysts.
- Johnson & Johnson
- Roche
- Otsuka Pharmaceutical
- Lundbeck
- Teva Pharmaceutical Industries
- Mylan N.V.
- Eisai Co. Ltd.
- Hikma Pharmaceuticals
- Akorn Inc.
- Sumitomo Dainippon Pharma
- AstraZeneca
Customization Options
Verified Industry Insights offers one of the following report customization options to our respectable clients :
Company Profiling
● Detailed profiling of additional market players (up to three players)
● SWOT analysis of key players (up to three players)
Competitive Benchmarking
● Benchmarking of key players on the following parameters : Product portfolio, geographical reach, regional presence, and strategic alliances.
Custom Research
Verified Industry Insights offers custom research services across sectors. In case of any custom research requirement related to market assessment, competitive benchmarking, sourcing and procurement, target screening, and others, please send your inquiry to [email protected] or call us at +1 743 222 5439
© 2024 Verified Industry Insights. All Rights Reserved